Clopidogrel

Drug Profile

Clopidogrel

Alternative Names: DV 7314; Iscover; PCR 4099; Plavix; SR 25989C; SR 25990C

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Bristol-Myers Squibb; Sanofi
  • Class 2 ring heterocyclic compounds; Antiplatelets; Chlorobenzenes; Esters; Pyridines; Small molecules; Thienopyridines
  • Mechanism of Action Platelet ADP receptor antagonists; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes; Angina pectoris; Atherosclerosis; Ischaemic heart disorders; Myocardial infarction; Peripheral arterial occlusive disorders; Stroke; Unstable angina pectoris
  • Registered Cardiovascular disorders
  • Discontinued Congenital heart defects

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 04 Oct 2012 Bristol-Myers Squibb intends to terminate its licence for clopidogrel in all countries except USA and Puerto Rico, effective 1 January 2013
  • 30 Sep 2012 Registered for Peripheral arterial occlusive disorders in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top